BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to AsPC1 cell line is 86
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting and IF staining | NA | 0.52 | 0.5695 | 25811929 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.52 | 0.5695 | 28703793 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qPCR and Western Blotting | NA | 0.52 | 0.5695 | 32575925 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.52 | 0.5695 | 30853342 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | qRT-PCR | NA | 0.52 | 0.5695 | 34163012 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qRT-PCR | NA | 0.52 | 0.5695 | 26391180 |
| LIN28A | 15986 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.0138 | 28703793 |
| LIN28A | 15986 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0138 | 27996162 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5461 | 28703793 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.5461 | 32575925 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 27996162 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 25811929 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 34163012 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | qRT-PCR and SFA | NA | 0.48 | 0.5461 | 33728488 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 27996162 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 30119228 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.6448 | 28703793 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.6448 | 32575925 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 27996162 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 30853342 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | qRT-PCR | NA | 0.48 | 0.6448 | 34163012 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | qRT-PCR and SFA | NA | 0.48 | 0.6448 | 33728488 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 35241126 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.6448 | 26391180 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 27996162 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 30119228 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA and FACs followed by Western Blotting | NA | 0.4 | 1 | 27996162 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by IF staining and FACs | NA | 0.4 | 1 | 26709750 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR and FACs | NA | 0.4 | 1 | 27996162 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.4 | 1 | 31440741 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | FACs and SFA | NA | 0.4 | 1 | 33728488 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | FACs followed by SFA | NA | 0.4 | 1 | 32575925 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.4 | 1 | 30119228 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.4 | 1 | 30853342 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Triptolide | SP assay followed by FACs | NA | 0.4 | 1 | 26597727 |
| ACAT2 | 94 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0032 | 27746256 |
| FASN | 3594 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Proteomics and Western Blotting | Up | 0.36 | 0.0074 | 27746256 |
| PARD1 | NA | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Proteomics and Western Blotting | Down | 0.36 | 0.0011 | 27746256 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by IF staining and FACs | NA | 0.36 | 0.456 | 26709750 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.36 | 0.456 | 31440741 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 27996162 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 27996162 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 30119228 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Triptolide | SP assay followed by FACs | NA | 0.36 | 0.456 | 26597727 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by IF staining and FACs | NA | 0.36 | 0.211 | 26709750 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.36 | 0.211 | 27996162 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.36 | 0.211 | 31440741 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR | NA | 0.36 | 0.211 | 27996162 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | FACs and SFA | NA | 0.36 | 0.211 | 33728488 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.36 | 0.211 | 30119228 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.36 | 0.211 | 30853342 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Triptolide | SP assay followed by FACs | NA | 0.36 | 0.211 | 26597727 |
| NES | 7756 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by IF staining and FACs | NA | 0.36 | 0.0573 | 26709750 |
| NES | 7756 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.36 | 0.0573 | 31440741 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by IF staining and FACs | NA | 0.36 | 0.7582 | 26709750 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA and FACs followed by qRT-PCR | NA | 0.36 | 0.7582 | 35241126 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | FACs followed by SFA and qPCR | NA | 0.36 | 0.7582 | 32575925 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.36 | 0.7582 | 31440741 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | FACs | NA | 0.36 | 0.7582 | 34163012 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | FACs | NA | 0.36 | 0.7582 | 26391180 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | FACs followed by SFA | NA | 0.36 | 0.7582 | 25811929 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.36 | 0.7582 | 30119228 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.36 | 0.7582 | 30853342 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SP assay followed by FACs | NA | 0.36 | 0.7582 | 22030254 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Triptolide | SP assay followed by FACs | NA | 0.36 | 0.7582 | 26597727 |
| MIR744 | 33658 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR and FACs | NA | 0.32 | 0.0021 | 26485754 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0604 | 30853342 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1739 | 30853342 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.684 | 30853342 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.28 | 0.684 | 31440741 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.28 | 0.684 | 27996162 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.28 | 0.684 | 27996162 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 25811929 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | Western Blotting | NA | 0.28 | 0.1135 | 23437065 |
| CTNNB1 | 2514 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 25811929 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0498 | 30853342 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.28 | 0.0498 | 31440741 |
| MYC | 7553 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.1304 | 25811929 |
| MYC | 7553 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | qRT-PCR | NA | 0.28 | 0.1304 | 34163012 |
| DCLK1 | 2700 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qPCR | NA | 0.2 | 0.0159 | 31440741 |
| KLF4 | 6348 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | qRT-PCR | NA | 0.2 | 0.0891 | 34163012 |
| MET | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.2 | 0.0191 | 27996162 |
| MET | 7029 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0191 | 26391180 |
| MET | 7029 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.2 | 0.0191 | 27996162 |
| MET | 7029 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by FACs | NA | 0.2 | 0.0191 | 30119228 |
| NR5A2 | 7984 | LTM | Pancreatic Cancer | Adenocarcinoma | AsPC1 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 27996162 |